Perindopril Use in End-Stage CKD

Introduction to Perindopril in CKD

The American College of Chest Physicians suggests that in patients with end-stage CKD, perindopril should be avoided due to safety concerns and lack of established efficacy, with well-managed vitamin K antagonists being the preferred option for cardiovascular protection when indicated 1

For cardiovascular protection in end-stage renal disease, guidelines suggest using well-managed vitamin K antagonists with TTR >65-70% rather than ACE inhibitors 1
In patients with severe non-dialysis CKD, selected NOACs may be used with caution based on pharmacokinetic data, but these should generally be avoided in end-stage CKD 1
Decision-making should be individualized for end-stage CKD patients, weighing potential cardiovascular benefits against increased risks of adverse effects 1

The PROGRESS study demonstrated that perindopril-based treatment reduced the risk of major vascular events by 30% and stroke by 35% among subjects with CKD, with greater absolute effects in those with CKD than without 2

If perindopril must be used in patients with CrCl >30 mL/min, monitor serum creatinine and potassium within 2-4 weeks after initiation or dose increase 3
Temporarily suspend ACE inhibitor therapy during intercurrent illness, planned IV radiocontrast administration, bowel preparation prior to colonoscopy, or prior to major surgery 4
Be vigilant for hyperkalemia, which is more common in advanced CKD patients on ACE inhibitors 4

For hypertension management in end-stage CKD, calcium channel blockers or beta-blockers may be safer alternatives 4
Many CKD patients will require combination therapy to achieve target blood pressure, and alternative agents like clonidine could be part of this regimen in selected patients 5